bioRxivCancer Biology
Evolutionary states and trajectories characterized by distinct pathways stratify ovarian high-grade serous carcinoma patients
A. Lahtinen, K. Lavikka, Y. Li, A. Virtanen, S. Jamalzadeh, K. Huhtinen, O. Carpen, S. Hietanen, A. Häkkinen, J. Hynninen, J. Oikkonen, S. Hautaniemi
Abstract
Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we characterized HGSC evolutionary states using whole-genome sequencing data from 214 samples of 55 HGSC patients in the prospective, longitudinal, multiregion DECIDER study. Comparison of the tissues revealed that site-of-origin samples have 70% more unique clones than the metastatic tumors or ascites. By integrating clonal composition and topology of HGSC tumors we discovered three evolutionary states that represent a continuum from genomically highly variable to stable tumors with significant association to treatment response. The states and their evolutionary trajectories were characterized by unique, targetable pathways, which were validated with RNA-seq data. Our study reveals that genomic heterogeneity is unaffected by the current standard-of-care and pinpoints effective treatment targets for each group. All genomics data are available via an interactive visualization platform for rapid exploration.
- organism: human
- assay: whole-genome sequencing
- assay: bulk RNA-seq
- research focus: clustering
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma
L. Geistlinger, S. Oh, … L. Waldron·bioRxiv·Jun 12, 2020
- The genomic landscape of early stage ovarian high grade serous carcinoma
Z. Cheng, H. Mirza, … I. McNeish·bioRxiv·May 5, 2021
- The mutational and clonality profile of HGSOC is established early in tumor development and conserved throughout therapy resistance
Michael Diaz, Nicole Gull, … Michelle R. Jones·bioRxiv·Feb 14, 2025
- Divergent trajectories to structural diversity impact patient survival in high grade serous ovarian cancer
A. Ewing, A. Meynert, … C. A. Semple·bioRxiv·Jan 12, 2024
- The genomic trajectory of ovarian high grade serous carcinoma is determined in STIC lesions
Z. Cheng, D. P. Ennis, … I. A. McNeish·bioRxiv·Mar 11, 2024
- Tracking clonal evolution of drug resistance in ovarian cancer patients by exploiting structural variants in cfDNA
Marc J. Williams, Ignacio Vázquez-Garćıa, … Sohrab P. Shah·NaturePeer-reviewed·Oct 1, 2025